Tenet Reports Results for the Fourth Quarter and Year Ended December 31, 2018 and Issues Outlook for 2019

Go back to Tenet Reports Results for the Fourth Quarter and Year Ended December 31, 2018 and Issues Outlook for 2019

Tenet Healthcare (THC) PT Raised to $29 at RBC Capital

February 27, 2019 7:21 AM EST

RBC Capital analyst Frank Morgan raised the price target on Tenet Healthcare (NYSE: THC) to $29.00 (from $26.00) while maintaining a Sector Perform rating.

... More

Tenet Healthcare (THC) PT Raised to $30 at Baird

February 26, 2019 8:13 AM EST

Baird analyst Matthew Gillmor raised the price target on Tenet Healthcare (NYSE: THC) to $30.00 (from $25.00) while maintaining a Neutral rating following Q4.

... More

Tenet Healthcare (THC) Tops Q4 EPS by 23c, Revenues Beat; Offers FY19 EPS Guidance Above Consensus, FY19 Revenue Mid-Point Views Abvoe Consensus, Provides Q1 EPS/Revenue Outlook

February 25, 2019 4:22 PM EST

Tenet Healthcare (NYSE: THC) reported Q4 EPS of $0.51, $0.23 better than the analyst estimate of $0.28. Revenue for the quarter came in at $4.62 billion versus the consensus estimate of $4.51 billion.

Tenet reported net income from continuing operations attributable to Tenet common shareholders of $108 million or $1.04 per diluted share in 2018. In the fourth quarter of 2018, Tenet reported a net loss from continuing operations attributable to Tenet common shareholders of $5 million or $0.05 per diluted share.Adjusted diluted earnings per share from continuing operations was $1.86 in 2018, above the Companys Outlook range of $1.44 to $1.83 and an increase... More